The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
Abstract
The beneficial actions of nonsteroidal anti‐inflammatory drugs (NSAIDs) have been linked to their ability to inhibit inducible COX‐2 at sites of inflammation, and their side effects (e.g., gastric damage) to inhibition of constitutive COX‐1. Selective inhibitors of COX‐2, such as celecoxib, etoricoxib, lumiracoxib, rofecoxib, and valdecoxib have been developed and the greatest recent growth in our knowledge in this area has been come from the clinical use of these compounds. Although clinical data indicate that COX‐2 selectivity is associated with a reduction in severe gastrointestinal events, they also reveal there are roles for constitutive COX‐2 within tissues such as the brain, kidney, pancreas, intestine, and blood vessels. We now better understand the roles of COX‐1 and COX‐2 in functions as disparate as the perception of pain and the progression of cancers. Clinical use of COX‐2‐selective compounds has ignited strong debates regarding potential side effects, most notably those within the cardiovascular system such as myocardial infarctions, strokes, and elevation in blood pressure. This review will discuss how the latest studies help us understand the roles of COX‐1 and COX‐2 and what clinically proven benefits the newer generation of COX‐2‐selective inhibitors offer.—Warner, T. D., Mitchell, J. A. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 18, 790–804 (2004)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Subbaramaiah, K., Lin, D. T., Hart, J. C., & Dannenberg, A. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007237200 · Cited by 275
RetractedBombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
Cyclooxygenases: Structural, cellular, and molecular biology
Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.145 · Cited by 2,925
Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.97 · Cited by 2,734
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Cyclooxygenase in biology and disease
DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., van de Putte, L. B. A., & Lipsky, P. E. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1063 · Cited by 2,506
Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., & Simmons, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162468699 · Cited by 1,989
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
Cited by
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., & Taubert, K. A. (2007) · Circulation · doi:10.1161/circulationaha.106.181424 · Cited by 804
Ginger—An Herbal Medicinal Product with Broad Anti-Inflammatory Actions
Grzanna, R., Lindmark, L., & Frondoza, C. G. (2005) · Journal of Medicinal Food · doi:10.1089/jmf.2005.8.125 · Cited by 778
Diclofenac: an update on its mechanism of action and safety profile
Gan, T. J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.486301 · Cited by 600
Current understanding of periodontal disease pathogenesis and targets for host‐modulation therapy
Hajishengallis, G., Chavakis, T., & Lambris, J. D. (2020) · Periodontology 2000 · doi:10.1111/prd.12331 · Cited by 502
Signalling networks regulating cyclooxygenase-2
Tsatsanis, C., Androulidaki, A., Venihaki, M., & Margioris, A. N. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.03.021 · Cited by 492
Phillis, J. W., Horrocks, L. A., & Farooqui, A. A. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.02.002 · Cited by 459
Cardiovascular effects and safety of (non-aspirin) NSAIDs
Schjerning, A.-M., McGettigan, P., & Gislason, G. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0366-z · Cited by 387
Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment
Renner, K., Singer, K., Koehl, G. E., Geissler, E. K., Peter, K., Siska, P. J., & Kreutz, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00248 · Cited by 374
Gutierrez, J., Ballinger, S. W., Darley-Usmar, V. M., & Landar, A. (2006) · Circulation Research · doi:10.1161/01.res.0000248212.86638.e9 · Cited by 318
Terra, X., Valls, J., Vitrac, X., Mérrillon, J.-M., Arola, L., Ardèvol, A., Bladé, C., Fernández-Larrea, J., Pujadas, G., Salvadó, J., et al. (2007) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf0633185 · Cited by 292
Cyclooxygenase Inhibition and Cardiovascular Risk
Antman, E. M., DeMets, D., & Loscalzo, J. (2005) · Circulation · doi:10.1161/circulationaha.105.568451 · Cited by 282
ZHANG, X., DONG, F., REN, J., DRISCOLL, M., & CULVER, B. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.10.011 · Cited by 280
Mitchell, J. A., & Warner, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1929 · Cited by 279
Self-citationDo Nonsteroidal Anti-Inflammatory Drugs Affect Bone Healing? A Critical Analysis
Pountos, I., Georgouli, T., Calori, G. M., & Giannoudis, P. V. (2012) · The Scientific World Journal · doi:10.1100/2012/606404 · Cited by 274
Schneider, V., Lévesque, L. E., Zhang, B., Hutchinson, T., & Brophy, J. M. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj331 · Cited by 270
Branco da Cunha, C., Klumpers, D. D., Li, W. A., Koshy, S. T., Weaver, J. C., Chaudhuri, O., Granja, P. L., & Mooney, D. J. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.06.047 · Cited by 268
Hop ( Humulus lupulus )-Derived Bitter Acids as Multipotent Bioactive Compounds
Van Cleemput, M., Cattoor, K., De Bosscher, K., Haegeman, G., De Keukeleire, D., & Heyerick, A. (2009) · Journal of Natural Products · doi:10.1021/np800740m · Cited by 263
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Muller, A. J., & Scherle, P. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1929 · Cited by 262
Microglia and neuroprotection: From in vitro studies to therapeutic applications
Polazzi, E., & Monti, B. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.009 · Cited by 262
Renal adverse effects of nonsteroidal anti-inflammatory drugs
Harirforoosh, S., & Jamali, F. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903311023 · Cited by 261
Shah, Y. M., Ito, S., Morimura, K., Chen, C., Yim, S., Haase, V. H., & Gonzalez, F. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.009 · Cited by 168
Cellular mechanisms of acetaminophen: role of cyclo‐oxygenase
Lucas, R., Warner, T. D., Vojnovic, I., & Mitchell, J. A. (2005) · The FASEB Journal · doi:10.1096/fj.04-2437fje · Cited by 128
Self-citationTurrin, N. P., & Rivest, S. (2004) · Experimental Biology and Medicine · doi:10.1177/153537020422901003 · Cited by 107
Pharmacologic Inhibition of COX-1 and COX-2 in Influenza A Viral Infection in Mice
Carey, M. A., Bradbury, J. A., Rebolloso, Y. D., Graves, J. P., Zeldin, D. C., & Germolec, D. R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011610 · Cited by 77
Hiraku, Y., Tabata, T., Ma, N., Murata, M., Ding, X., & Kawanishi, S. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00497.x · Cited by 71
Lipid mediators and allergic diseases
Fanning, L. B., & Boyce, J. A. (2013) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2013.06.031 · Cited by 70
The electrophile responsive proteome: Integrating proteomics and lipidomics with cellular function
Higdon, A. N., Landar, A., Barnes, S., & Darley-Usmar, V. M. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4523 · Cited by 51
Therapeutic Potential and Predictive Pharmaceutical Modeling of Stilbenes in Cannabis sativa
O’Croinin, C., Garcia Guerra, A., Doschak, M. R., Löbenberg, R., & Davies, N. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071941 · Cited by 25
“Although the inhibition of COX1 is associated with gastric ulceration, the subsequent inhibition of COX2 is well-established to be anti-inflammatory through the inhibition of prostaglandin formation, with NSAIDs working through this pathway [15].”
BackgroundInfluentialMilani, G. P., Nicolini, G., Cananzi, M., Spiezia, L., & Vidal, E. (2026) · Children · doi:10.3390/children13010071 · Cited by 5
Metadata
- Authors
- Warner, T. D., & Mitchell, J. A.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2004-05
- Volume
- 18
- Issue
- 7
- Pages
- 790-804
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2076744535
- Cited by
- 614
- References
- 135
- FWCI
- 35.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.